Document is current
Any future updates will be listed below
-
Authors
,
Löffler, Markus W. http://orcid.org/0000-0003-2513-1317
Mohr, Christopher
Bichmann, Leon
Freudenmann, Lena Katharina
Walzer, Mathias
Schroeder, Christopher M.
Trautwein, Nico
Hilke, Franz J.
Zinser, Raphael S.
Mühlenbruch, Lena
Kowalewski, Daniel J.
Schuster, Heiko
Sturm, Marc
Matthes, Jakob
Riess, Olaf
Czemmel, Stefan
Nahnsen, Sven
Königsrainer, Ingmar
Thiel, Karolin
Nadalin, Silvio
Beckert, Stefan
Bösmüller, Hans
Fend, Falko
Velic, Ana
Maček, Boris
Haen, Sebastian P.
Buonaguro, Luigi
Kohlbacher, Oliver
Stevanović, Stefan
Königsrainer, Alfred
Rammensee, Hans-Georg
- License Information
-
More Information
Article History
Received: 22 January 2019
Accepted: 3 April 2019
First Online: 30 April 2019
Ethics approval and consent to participate
: This study was conducted in accordance with the Declaration of Helsinki and applicable laws and regulations and has been approved by the local institutional review board at the University Hospital of Tübingen, Germany (Project No. 364/2014BO2). All participants provided written informed consent before study inclusion.
: Not applicable.
: M.W. Löffler, D.J. Kowalewski, H. Schuster, S. Stevanović, and S.P. Haen are the inventors of patents owned by Immatics Biotechnologies GmbH. D.J. Kowalewski and H. Schuster are currently employees of Immatics Biotechnologies GmbH. H.G. Rammensee has ownership interest (including patents) in Immatics Biotechnologies GmbH, CureVac AG, and Synimmune GmbH. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
